04.07.2024 • News

Syensqo and Allozymes to Develop Biosolutions for Home and Personal Care

Belgium-headquartered specialty materials producer Syensqo and Allozymes, a Singaporean enzyme engineering start-up, have signing of a Memorandum of Understanding (MoU) to leverage both companies’ expertise in biotechnology to develop advanced biosolutions for home and personal care, particularly for the skin care market.

Allozymes has developed a proprietary ultra-high throughput microfluidics platform for the engineering of enzymes and microbes which enables the rapid and cost-effective development of biomanufactured ingredients and bioprocesses.

“By combining Allozymes technological capabilities with Syensqo's application and market access expertise, we are poised to create groundbreaking solutions that will not only benefit the home and personal care market but also contribute to a more sustainable future,” said Thomas Canova, head of Renewable Materials & Biotechnology growth platform at Syensqo.

Syensqo said that this MoU marks an important milestone in its strategic agenda of rapidly expanding its beauty specialty ingredients portfolio based on biotechnology and complements the company's recent acquisition of South Korean ceramides specialist JinYoung Bio.

“Our partnership with Syensqo embodies our mutual commitment to a sustainable future, leveraging biotechnology to enable cleaner, greener processes, ensuring our actions today contribute to a healthier planet for future generations. Together, we're setting a new standard for environmental stewardship," commented Peyman Salehian, CEO and co-founder at Allozymes.

© Getty Images
© Getty Images

Company

Syensqo

rue de la Fusée 98
B-1130 Brussels
Belgium

Company contact







Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.